Daily Sepsis Research Analysis
Analyzed 42 papers and selected 3 impactful papers.
Summary
Analyzed 42 papers and selected 3 impactful articles.
Selected Articles
1. Real-world clinical outcomes of macrophage activation-like syndrome and hyperferritinemia in sepsis: a retrospective database analysis.
Among over 224,000 sepsis patients, MALS (ferritin ≥4420 ng/mL) was associated with substantially higher 28- and 90-day mortality and greater need for intubation, ICU admission, CRRT, and vasopressors compared with matched non-MALS patients. Mortality increased stepwise with higher ferritin thresholds, even below 4420 ng/mL; exploratory anakinra use was not associated with survival benefit.
Impact: This large, rigorously matched real-world cohort quantifies the risk gradient of hyperferritinemia in sepsis and challenges current MALS thresholds, directly informing risk stratification and triage.
Clinical Implications: Obtain early ferritin in suspected hyperinflammatory sepsis to refine risk stratification and anticipate escalated organ support needs; do not assume benefit from IL-1 blockade (anakinra) without trial evidence.
Key Findings
- MALS (ferritin ≥4420 ng/mL) had higher 28-day (HR 2.73) and 90-day (HR 2.49) mortality versus matched non-MALS sepsis.
- MALS was associated with increased intubation, ICU admission, CRRT, and vasopressor use at both 28 and 90 days.
- Mortality rose stepwise with higher ferritin cutoffs (e.g., 2000–10,000 ng/mL), indicating risk even below standard MALS thresholds.
- Exploratory analysis showed no survival improvement with anakinra at day 14 or day 28.
- Older age, bacteremia, and immunocompromised status amplified adverse outcomes in MALS.
Methodological Strengths
- Very large multi-institutional cohort with 1:1 propensity score matching and subgroup analyses
- Evaluation across multiple ferritin thresholds with time-to-event outcomes (28- and 90-day)
Limitations
- Retrospective design with residual confounding and selection bias (ferritin measured subset)
- No randomized testing of therapies; anakinra analysis was exploratory and non-randomized
Future Directions: Prospective validation of ferritin-based risk stratification and randomized trials testing MALS-targeted immunomodulation are warranted.
BACKGROUND: Macrophage activation-like syndrome (MALS) is characterized by hyperferritinemia, yet its clinical course in real-world practice and the prognostic and clinical significance of varying ferritin levels have not been fully defined. The aim of this study was to characterize the epidemiology and clinical outcomes associated with sepsis and MALS. METHODS: We performed a retrospective analysis of the TriNetX database, identifying sepsis patients with MALS and ferritin level ≥4420 ng/mL within 3 days of diagnosis; patients with sepsis and ferritin <4420 ng/mL were classified as no-MALS. Primary outcomes were 28-day and 90-day all-cause mortality, and secondary outcomes included need for endotracheal intubation, intensive care unit (ICU) admission, continuous renal replacement therapy (CRRT), and vasopressors. We performed subgroup analyses according to age, immune suppression status, and bacteremia and assessed varying ferritin cutoff values (2000, 3000, 4420, 6000, and 10,000 ng/mL) for MALS diagnosis against study outcomes.
2. A multicentre evaluation of pharmacokinetic/pharmacodynamic target attainment of piperacillin and tazobactam and the association with clinical outcomes in critically ill patients with sepsis and septic shock.
In a prospective multicenter PK/PD study of 45 ICU patients with sepsis or septic shock, only 54% (day 1) and 44% (day 3) met predefined therapeutic exposures. Creatinine clearance drove clearance, and simulations supported a 4.5 g loading dose then 4.5 g q6h by continuous infusion to optimize safe target attainment for CLcr 50–130 mL/min.
Impact: Provides dosing guidance grounded in PK/PD and simulations, highlighting underexposure with intermittent dosing and supporting continuous infusion—a practice-changing insight in septic ICU patients.
Clinical Implications: Consider continuous infusion piperacillin/tazobactam with an initial loading dose, especially in patients with preserved renal function, and integrate renal function into dosing to avoid underexposure.
Key Findings
- Only 54% (day 1) and 44% (day 3) achieved predefined PK/PD targets for piperacillin/tazobactam.
- A one-compartment, first-order elimination model fit both drugs; creatinine clearance significantly influenced clearance.
- Monte Carlo simulations supported a 4.5 g loading dose followed by 4.5 g every 6 h as continuous infusion (CLcr 50–130 mL/min).
- Exposure-optimized patients tended to be older with lower CLcr; exploratory outcome differences were not statistically significant.
- Maintaining piperacillin concentrations below toxicity threshold (<160 mg/L) was feasible with recommended regimen.
Methodological Strengths
- Prospective multicenter sampling on days 1 and 3 with validated bioanalytical assay
- Population PK modeling with Monte Carlo simulations to inform dosing
Limitations
- Small sample size limiting power to detect clinical outcome differences
- Total (not unbound) concentrations measured; external generalizability beyond study ICUs is uncertain
Future Directions: Randomized or adaptive trials comparing continuous versus intermittent infusion with therapeutic drug monitoring to confirm clinical benefits.
OBJECTIVES: To characterize the population pharmacokinetics and pharmacokinetic/pharmacodynamic target attainment of piperacillin and tazobactam in critically ill patients with sepsis or septic shock in Malaysian intensive care units and to use the population pharmacokinetic model to estimate individual target attainment and explore associations with clinical outcomes. METHODS: Serial blood samples were collected on days 1 and 3 of therapy in this prospective multicentre study. Total plasma piperacillin and tazobactam concentrations were quantified using a validated chromatographic assay. Population pharmacokinetic analysis and Monte Carlo dosing simulations were performed using Monolix. Therapeutic exposure was defined as achieving 100% fT>16 mg/L for piperacillin and 85% fT>2 mg/L for tazobactam while remaining below the piperacillin toxicity threshold (<160 mg/L). RESULTS: Forty-five critically ill adults with sepsis or septic shock were recruited (median age, 61 years [range: 18-88]; median creatinine clearance (CLcr) 70 mL/min [range: 30-161]; 20 females). A one-compartment model with first-order elimination best described the pharmacokinetics for both drugs. Estimated CLcr significantly influenced drug clearance. Pre-defined therapeutic exposures were achieved in 54% and 44% on days 1 and 3, respectively. Patients attaining exposures were older and had lower CLcr. Clinical cure and ICU survival were numerically different across exposure groups, although these exploratory comparisons were not statistically significant. Simulations indicated that a 4.5 g loading dose followed by 4.5 g every 6 h as a continuous infusion achieved effective and safe exposures in patients with CLcr 50 to 130 mL/min. CONCLUSION: Continuous infusion is the most reliable strategy for achieving early piperacillin/tazobactam therapeutic exposures in patients with sepsis or septic shock.
3. Timing of renal-replacement therapy in patients with acute kidney injury and sepsis: a systematic review and meta-analysis.
Pooling 15 studies (4 RCTs, 11 cohorts; 6,289 patients), early RRT initiation in sepsis-associated AKI reduced 28-day mortality (RR 0.81) but lost significance after trim-and-fill adjustment (RR 0.88) and showed no benefit for 90-day mortality, MODS, or length of stay. Heterogeneity and mixed designs suggest individualized strategies over fixed timing rules.
Impact: Synthesizes the best available evidence on a pivotal management question in sepsis-associated AKI, clarifying that any mortality benefit of early RRT may be short-term and sensitive to bias.
Clinical Implications: Adopt individualized triggers (metabolic, fluid, hemodynamic) for RRT initiation rather than rigid early/delayed rules, and prioritize trials integrating biomarkers and dynamic assessments.
Key Findings
- Early RRT reduced 28-day mortality (RR 0.81), with moderate heterogeneity (I²≈31%).
- After trim-and-fill adjustment for publication bias, 28-day mortality benefit lost statistical significance (RR 0.88).
- No significant differences for 90-day mortality, MODS, ICU stay, or hospital stay.
- Evidence base comprised both RCTs (n=4) and retrospective cohorts (n=11), contributing to heterogeneity.
Methodological Strengths
- Comprehensive multi-database search including RCTs and cohorts with random-effects modeling
- Bias assessment with trim-and-fill to test robustness of mortality findings
Limitations
- Mixed study designs and variable definitions of 'early' vs 'delayed' RRT introduce heterogeneity
- Potential residual confounding in observational data; lack of consistent patient-level criteria
Future Directions: Adaptive, biomarker-guided RRT timing trials in sepsis-associated AKI, harmonizing definitions and focusing on patient-centered outcomes beyond 90 days.
BACKGROUND: The optimal timing for initiating renal replacement therapy (RRT) in sepsis-associated acute kidney injury (AKI) patients remains controversial. Early RRT initiation offers benefits by preventing metabolic complications and fluid overload, while delayed initiation avoids unnecessary procedures and conserves resources. This systematic review and meta-analysis aimed to compare early versus delayed RRT strategies in adult patients with sepsis-associated AKI. METHODS: We conducted a comprehensive search on PubMed, Scopus, Web of Science, and Cochrane CENTRAL from inception to February 2026. We included randomized controlled trials (RCTs) and observational cohorts comparing early versus delayed RRT initiation in patients with sepsis-associated AKI. Outcomes included 28-day and 90-day mortality, multi-organ dysfunction score (MODS), and intensive care unit (ICU) and hospital length of stay. Data were pooled using random-effects models. RESULTS: Fifteen studies (4 RCTs, 11 retrospective cohorts) comprising 6,289 patients were included. Early RRT was associated with significant reduction in 28-day mortality compared to delayed RRT (RR 0.81, 95% CI: 0.68-0.95, p = 0.01; I²=31.38%). However, trim-and-fill analysis suggested potential publication bias, with adjusted estimates showing non-significance (RR 0.88, 95% CI: 0.75-1.04). No significant differences were observed for 90-day mortality (RR 0.85, 95% CI: 0.69-1.04, p = 0.12), MODS (MD 0.24, 95% CI: -0.94-1.42, p = 0.69), ICU length of stay (MD -1.76, 95% CI: -4.18-0.66, p = 0.15), or hospital length of stay (MD 0.34, 95% CI: -3.24-3.92, p = 0.85). CONCLUSION: Early RRT initiation in sepsis-associated AKI was associated with reduction in 28-day mortality rates but did not result in any differences of 90-days mortality rates, and was not associated with improvements in MODS, suggesting that timing alone may not substantially alter long-term outcomes in this high-risk population. These findings are driven from mixed study designs with heterogeneity among the included patients, underscoring the need for more individualized approaches to RRT initiation in the future trials. TRIAL REGISTRATION: Not applicable.